NIH ACTIV vaccine working group weighs role of human challenge studies for SARS-CoV-2 vaccine development

Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).   NIH ACTIV vaccine working group weighs role of human challenge studies for SARS-CoV-2 vaccine development 07/01/2020 05:00 PM EDT The authors conclude that large, randomized, controlled trials of SARS-CoV-2 are the fastest and most effective path forward for establishing vaccine safety and efficacy. Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®      This email was sent to ymilov@gmail.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612